ArticleScientific reports2025
Identification of biomarkers and mechanisms associated with palmitoylation in acute kidney injury using transcriptome and single cell data.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Food Contaminant to Therapeutic Target: Identification of KCNE2 and 5-Azacytidine for Gastric Cancer via Multi-Omics, Machine Learning, and In Vitro Validation.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Palmitoylation is implicated in acute kidney injury (AKI) development, but its mechanisms are poorly understood. Our study aimed to identify biomarkers associated with palmitoylation-related genes (PRGs) in AKI and explore their biological mechanisms. We analyzed datasets GSE139061, GSE30718, and GSE174220, identifying intersecting genes through differential expression and WGCNA. Candidate genes were selected via PPI analysis, and biomarkers were identified using machine learning, ROC analysis, and gene expression analysis. A nomogram was constructed, and functional analysis along with Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) and Western blotting were performed. scRNA-seq analysis was utilized to identify key cell types and their developmental trajectories in AKI. LIMD1 and MBD2 were identified as AKI biomarkers with elevated expression in AKI samples, confirmed by RT-qPCR and Western blotting. A nomogram based on these biomarkers effectively predicted AKI risk. Functional analysis showed co-enrichment in the "valine leucine and isoleucine degradation" pathway. scRNA-seq analysis identified tubular cells as key in AKI pathogenesis, with a developmental trajectory detailed through pseudo-time analysis. LIMD1 and MBD2 were confirmed as AKI biomarkers, with tubular cells identified as crucial in AKI. Our findings provide new insights into AKI treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.